Observational studyInternational ophthalmology2025
Preliminary evaluation on the effect of oral omega-3 supplementation from herring caviar oil in primary open-angle glaucoma patients.
Observational study in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of a High-Fat Diet on Eye Health.Nutrients · 2025Pooled it
- Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study.Translational vision science & technology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe study aimed to assess the neuroprotective effect of phospholipid-rich omega-3 fatty acids from herring caviar oil in POAG patients with intraocular pressure (IOP) control.
methodsA single-center, observational, short-term, preliminary evaluation of three months was conducted. Fifty eyes of POAG patients with IOP were included and divided into the control group (n = 31) and the intervention group (n = 19) receiving one capsule of omega-3 fatty acids supplementation per day. All the participants underwent comprehensive clinical assessment at baseline and 3 months, including best-corrected visual acuity (BCVA), IOP, visual field (VF) test, optical coherence tomography (OCT). Primary outcomes were median deviation (MD) and pattern standard deviation (PSD) scores of VF, while secondary outcomes included BCVA, IOP, retinal nerve fiber layer thickness (RNFLT) of OCT, and adverse events.
resultsAt baseline, no significant differences were observed between the 50 patients in terms of age, sex, antiglaucomatous medications, BCVA, IOP, VF, or RNFLT. After three months, the intervention group exhibited a statistically significant improvement in MD value (p = 0.01). The change of PSD revealed a slightly greater reduction in the intervention group compared to controls, albeit with borderline significance (p = 0.08). A minor decrease in IOP was noted in the intervention group at three months, compared to the control group (p = 0.07). No significant differences were observed in other secondary outcomes, and no adverse events were reported.
conclusionOral omega-3 fatty acids supplementation derived from herring caviar oil is potentially neuroprotective and safe for IOP-controlled POAG patients, and it may serve as a clinically valuable additional option. However, these results necessitate confirmation with an appropriately designed randomized controlled study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.